These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 35860008)
1. Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer. Jin Y; Lorvik KB; Jin Y; Beck C; Sike A; Persiconi I; Kvaløy E; Saatcioglu F; Dunn C; Kyte JA Mol Ther Oncolytics; 2022 Sep; 26():189-206. PubMed ID: 35860008 [TBL] [Abstract][Full Text] [Related]
2. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. Jin Y; Dunn C; Persiconi I; Sike A; Skorstad G; Beck C; Kyte JA Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203757 [TBL] [Abstract][Full Text] [Related]
3. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Bhatia V; Kamat NV; Pariva TE; Wu LT; Tsao A; Sasaki K; Sun H; Javier G; Nutt S; Coleman I; Hitchcock L; Zhang A; Rudoy D; Gulati R; Patel RA; Roudier MP; True LD; Srivastava S; Morrissey CM; Haffner MC; Nelson PS; Priceman SJ; Ishihara J; Lee JK Nat Commun; 2023 Apr; 14(1):2041. PubMed ID: 37041154 [TBL] [Abstract][Full Text] [Related]
4. Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy. Beck C; Casey NP; Persiconi I; Moharrami NN; Sike A; Jin Y; Kyte JA Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36830995 [TBL] [Abstract][Full Text] [Related]
5. Targeting STEAP1 as an anticancer strategy. Nakamura H; Arihara Y; Takada K Front Oncol; 2023; 13():1285661. PubMed ID: 37909017 [TBL] [Abstract][Full Text] [Related]
6. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Nolan-Stevaux O; Li C; Liang L; Zhan J; Estrada J; Osgood T; Li F; Zhang H; Case R; Murawsky CM; Estes B; Moore GL; Bernett MJ; Muchhal U; Desjarlais JR; Staley BK; Stevens J; Cooke KS; Aeffner F; Thomas O; Stieglmaier J; Lee JL; Coxon A; Bailis JM Cancer Discov; 2024 Jan; 14(1):90-103. PubMed ID: 37861452 [TBL] [Abstract][Full Text] [Related]
8. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737 [TBL] [Abstract][Full Text] [Related]
9. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A Front Immunol; 2021; 12():665970. PubMed ID: 34475869 [TBL] [Abstract][Full Text] [Related]
10. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942 [TBL] [Abstract][Full Text] [Related]
11. Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis by aiding progression of epithelial-to-mesenchymal transition. Jiao Z; Huang L; Sun J; Xie J; Wang T; Yin X; Zhang H; Chen J Histochem Cell Biol; 2020 Aug; 154(2):215-230. PubMed ID: 32382787 [TBL] [Abstract][Full Text] [Related]
12. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256 [TBL] [Abstract][Full Text] [Related]
13. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer. Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314 [TBL] [Abstract][Full Text] [Related]
14. STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland. Maia CJ; Socorro S; Schmitt F; Santos CR Endocrine; 2008; 34(1-3):108-16. PubMed ID: 18958632 [TBL] [Abstract][Full Text] [Related]
15. Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies. Zhang J; Chadha JS Cancers (Basel); 2024 Sep; 16(17):. PubMed ID: 39272956 [TBL] [Abstract][Full Text] [Related]
16. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018 [TBL] [Abstract][Full Text] [Related]
17. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. Hillerdal V; Ramachandran M; Leja J; Essand M BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073 [TBL] [Abstract][Full Text] [Related]
18. STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer. Xu M; Evans L; Bizzaro CL; Quaglia F; Verrillo CE; Li L; Stieglmaier J; Schiewer MJ; Languino LR; Kelly WK Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011027 [TBL] [Abstract][Full Text] [Related]
19. Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells. Iijima K; Nakamura H; Takada K; Hayasaka N; Kubo T; Umeyama Y; Iyama S; Miyanishi K; Kobune M; Kato J Oncol Lett; 2021 Jul; 22(1):546. PubMed ID: 34335918 [TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]